UNSPSC 51434955: Polythiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434955 Polythiazide/reserpine, a Commodity code, comprises prescription and over-the-counter pharmaceutical products that state and local governments procure for emergency medical services, pharmacy benefit programs, and institutional health care delivery. State and local procurement activity under this code centers on acquiring medications for fire rescue operations, state health agencies managing pharmacy benefits for employee and Medicaid populations, and multistate cooperative purchasing consortia sourcing generic pharmaceuticals for participating jurisdictions. Soliciting bodies include city purchasing departments (Tampa), state health and human services agencies (Texas HHS Commission), and multistate purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance). The work involves competitive bidding or RFP processes to establish supply contracts with qualified manufacturers and wholesalers, often requiring vendors to maintain compliance with cGMP and Drug Supply Chain Security Act standards, provide detailed product specifications including NDCs and UPCs, and meet stringent expiration-date and shelf-life requirements.

Activity under the code spans Florida, Texas, and Minnesota, with recent solicitations reflecting both direct municipal procurement and statewide cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with specific vial and injection products under a one-year contract with renewal options, estimated at $40,000 and sheltered for Small Local Business Enterprises at a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers across participating state and local facilities in Minnesota and Oregon, with contracts effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs without traditional PBM intermediation, positioning the state for a future formal RFP focused on pharmacy benefit innovation and cost management.